Vimarsana
Biggest News Aggregation in the World

Page 12 - Arnaud Delepine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnaud Delepine Today - Breaking & Trending Today

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting - Vimarsana News

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting oncology pipeline at 2021 ASCO Meeting Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer Data that reinforce Libtayo (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer and advanced non-small cell lung cancer, including new data in historically underrepresented patients with brain metastases Longer term data and new analyses for Sarclisa (isatuximab-ir...

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer - Vimarsana News

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Share this article PARIS, May 19, 2021 /PRNewswire/ --  Phase 1 data from the AMEERA-1 study evaluating amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. In a pooled analysis, amcenestrant in combination with palbociclib showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). "These early clinical data show that the combination of amcenes...

Pivotal data at ATS 2021 show Dupixent® (dupilumab) - Vimarsana News

Pivotal data at ATS 2021 show Dupixent® (dupilumab)

        Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children Dupixent is the...

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research - Vimarsana News

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research Projects led by collaborating researchers from the two organizations will focus on autoimmune

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands - Vimarsana News

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

Share this article Share this article BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs. Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna's COVID-19 vaccine, starting in September 2021. "Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity ...